Connection

Michael Zile to Humans

This is a "connection" page, showing publications Michael Zile has written about Humans.
Connection Strength

2.517
  1. Hemodynamically-Guided Management of Heart?Failure Across the Ejection?Fraction Spectrum: The GUIDE-HF Trial. JACC Heart Fail. 2022 Dec; 10(12):931-944.
    View in: PubMed
    Score: 0.032
  2. The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic. Eur Heart J. 2022 07 14; 43(27):2603-2618.
    View in: PubMed
    Score: 0.031
  3. A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone. Circulation. 2021 10 19; 144(16):1269-1271.
    View in: PubMed
    Score: 0.029
  4. From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited. Circ Res. 2021 05 14; 128(10):1451-1467.
    View in: PubMed
    Score: 0.029
  5. The Vexing Problem of HFpEF?Therapeutics: Inching Toward Success. JACC Heart Fail. 2021 05; 9(5):371-373.
    View in: PubMed
    Score: 0.029
  6. Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovasc Disord. 2021 03 26; 21(1):155.
    View in: PubMed
    Score: 0.028
  7. INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2021 04; 8(2):849-860.
    View in: PubMed
    Score: 0.028
  8. Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. Clin Cardiol. 2020 Dec; 43(12):1501-1510.
    View in: PubMed
    Score: 0.027
  9. Prediction of heart failure hospitalizations based on the direct measurement of intrathoracic impedance. ESC Heart Fail. 2020 10; 7(5):3040-3048.
    View in: PubMed
    Score: 0.027
  10. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. J Am Coll Cardiol. 2020 08 04; 76(5):503-514.
    View in: PubMed
    Score: 0.027
  11. Baroreflex Activation Therapy in Patients With Heart?Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2020 07 07; 76(1):1-13.
    View in: PubMed
    Score: 0.027
  12. Should We Test for Diastolic Dysfunction? How and How Often? JACC Cardiovasc Imaging. 2020 01; 13(1 Pt 2):297-309.
    View in: PubMed
    Score: 0.025
  13. Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure. Am J Cardiol. 2019 09 01; 124(5):756-762.
    View in: PubMed
    Score: 0.025
  14. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients?With HFrEF. J Am Coll Cardiol. 2019 02 26; 73(7):795-806.
    View in: PubMed
    Score: 0.025
  15. First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. Am Heart J. 2018 10; 204:139-150.
    View in: PubMed
    Score: 0.024
  16. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 05; 11(5):e004446.
    View in: PubMed
    Score: 0.023
  17. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 07; 6(7):547-554.
    View in: PubMed
    Score: 0.023
  18. Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium. Physiol Rep. 2017 Nov; 5(20).
    View in: PubMed
    Score: 0.022
  19. Palliative Care for Advanced Heart Failure in a Department of Veterans Affairs Regional Hospice Program: Patient Selection, a Treatment Protocol, and Clinical Course. J Palliat Med. 2017 10; 20(10):1068-1073.
    View in: PubMed
    Score: 0.022
  20. Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. Circ Heart Fail. 2017 Jan; 10(1).
    View in: PubMed
    Score: 0.021
  21. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016 Dec 06; 68(22):2425-2436.
    View in: PubMed
    Score: 0.021
  22. Could Modification of Titin Contribute to an Answer for Heart Failure With Preserved Ejection Fraction? Circulation. 2016 10 11; 134(15):1100-1104.
    View in: PubMed
    Score: 0.021
  23. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. Semin Thorac Cardiovasc Surg. 2016 Summer; 28(2):320-328.
    View in: PubMed
    Score: 0.020
  24. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.020
  25. Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance. Circ Heart Fail. 2016 Jan; 9(1):e002543.
    View in: PubMed
    Score: 0.020
  26. Is Biventricular Fibrosis the Mediator of Late Complications in Tetralogy of Fallot? JACC Cardiovasc Imaging. 2016 Jan; 9(1):11-3.
    View in: PubMed
    Score: 0.020
  27. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail. 2015 Oct; 17(10):1066-74.
    View in: PubMed
    Score: 0.019
  28. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015 Apr 07; 131(14):1247-59.
    View in: PubMed
    Score: 0.019
  29. Adverse left ventricular remodeling in community-dwelling older adults predicts incident heart failure and mortality. JACC Heart Fail. 2014 Oct; 2(5):512-22.
    View in: PubMed
    Score: 0.018
  30. Renal sympathetic denervation for blood pressure control: a review of the current evidence and ongoing studies. J Clin Hypertens (Greenwich). 2014 May; 16(5):331-41.
    View in: PubMed
    Score: 0.017
  31. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail. 2014 Apr; 2(2):123-30.
    View in: PubMed
    Score: 0.017
  32. Integrating the myocardial matrix into heart failure recognition and management. Circ Res. 2013 Aug 30; 113(6):725-38.
    View in: PubMed
    Score: 0.017
  33. Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res. 2013 Aug; 6(4):501-15.
    View in: PubMed
    Score: 0.016
  34. Neuromodulation device therapy for treatment of hypertensive heart disease. Circ J. 2013; 77(6):1351-63.
    View in: PubMed
    Score: 0.016
  35. Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circ Heart Fail. 2013 May; 6(3):508-16.
    View in: PubMed
    Score: 0.016
  36. Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013 Jan 04; 112(1):195-208.
    View in: PubMed
    Score: 0.016
  37. HFpEF: cardiovascular abnormalities not just comorbidities. Circ Heart Fail. 2012 Nov; 5(6):669-71.
    View in: PubMed
    Score: 0.016
  38. Effects of autonomic modulation: more than just blood pressure. J Am Coll Cardiol. 2012 Mar 06; 59(10):910-2.
    View in: PubMed
    Score: 0.015
  39. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.015
  40. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011 Dec 06; 124(23):2491-501.
    View in: PubMed
    Score: 0.015
  41. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol. 2011 Oct 18; 58(17):1733-40.
    View in: PubMed
    Score: 0.015
  42. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet. 2011 Dec; 4(6):614-9.
    View in: PubMed
    Score: 0.015
  43. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
    View in: PubMed
    Score: 0.015
  44. Abnormal calcium homeostasis: one mechanism in diastolic heart failure. J Am Coll Cardiol. 2011 Jul 05; 58(2):155-7.
    View in: PubMed
    Score: 0.014
  45. Hemodynamic factors associated with acute decompensated heart failure: part 1--insights into pathophysiology. J Card Fail. 2011 Apr; 17(4):282-91.
    View in: PubMed
    Score: 0.014
  46. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011 May; 4(3):246-56.
    View in: PubMed
    Score: 0.014
  47. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail. 2011 Feb; 17(2):167-78.
    View in: PubMed
    Score: 0.014
  48. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010 Mar 30; 121(12):1393-405.
    View in: PubMed
    Score: 0.013
  49. Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic flow therapy) in patients hospitalized with severe heart failure: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). J Heart Lung Transplant. 2010 Jan; 29(1):86-92.
    View in: PubMed
    Score: 0.013
  50. Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. Am J Cardiol. 2009 Nov 15; 104(10):1413-5.
    View in: PubMed
    Score: 0.013
  51. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008 Sep 30; 118(14):1433-41.
    View in: PubMed
    Score: 0.012
  52. Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. J Card Fail. 2008 Dec; 14(10):816-23.
    View in: PubMed
    Score: 0.012
  53. Patterns of structural and functional remodeling of the left ventricle in chronic heart failure. Am J Cardiol. 2008 Aug 15; 102(4):459-62.
    View in: PubMed
    Score: 0.012
  54. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
    View in: PubMed
    Score: 0.011
  55. Left ventricular end-diastolic volume is normal in patients with heart failure and a normal ejection fraction: a renewed consensus in diastolic heart failure. J Am Coll Cardiol. 2007 Mar 06; 49(9):982-5.
    View in: PubMed
    Score: 0.011
  56. New molecular mechanism in diastolic heart failure. Circulation. 2006 Apr 25; 113(16):1922-5.
    View in: PubMed
    Score: 0.010
  57. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006 May 02; 113(17):2089-96.
    View in: PubMed
    Score: 0.010
  58. Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. Circulation. 2005 Jul 19; 112(3):300-3.
    View in: PubMed
    Score: 0.010
  59. Diastolic heart failure: definitions and terminology. Prog Cardiovasc Dis. 2005 Mar-Apr; 47(5):307-13.
    View in: PubMed
    Score: 0.009
  60. A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. J Card Fail. 2004 Jun; 10(3):193-9.
    View in: PubMed
    Score: 0.009
  61. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004 May 06; 350(19):1953-9.
    View in: PubMed
    Score: 0.009
  62. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004; 55:373-94.
    View in: PubMed
    Score: 0.009
  63. Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol. 2003 May 07; 41(9):1519-22.
    View in: PubMed
    Score: 0.008
  64. Heart failure in aortic stenosis - improving diagnosis and treatment. N Engl J Med. 2003 May 01; 348(18):1735-6.
    View in: PubMed
    Score: 0.008
  65. Diastolic heart failure. Diagnosis, prognosis, treatment. Minerva Cardioangiol. 2003 Apr; 51(2):131-42.
    View in: PubMed
    Score: 0.008
  66. Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. Eur Heart J. 2023 02 21; 44(8):668-677.
    View in: PubMed
    Score: 0.008
  67. Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2023 02 01; 8(2):150-158.
    View in: PubMed
    Score: 0.008
  68. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial. Circ Heart Fail. 2023 03; 16(3):e010111.
    View in: PubMed
    Score: 0.008
  69. Structural components of cardiomyocyte remodeling: summation. J Card Fail. 2002 Dec; 8(6 Suppl):S311-3.
    View in: PubMed
    Score: 0.008
  70. Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. Eur Heart J. 2022 11 07; 43(42):4469-4479.
    View in: PubMed
    Score: 0.008
  71. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2022 09 20; 80(12):1130-1143.
    View in: PubMed
    Score: 0.008
  72. Aptamer Proteomics for Biomarker Discovery in Heart Failure With Reduced Ejection Fraction. Circulation. 2022 Nov; 146(18):1411-1414.
    View in: PubMed
    Score: 0.008
  73. Baroreflex activation therapy with the Barostim? device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. Eur J Heart Fail. 2022 09; 24(9):1665-1673.
    View in: PubMed
    Score: 0.008
  74. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022 06 18; 21(1):110.
    View in: PubMed
    Score: 0.008
  75. Mechanisms that limit regression of myocardial fibrosis following removal of left ventricular pressure overload. Am J Physiol Heart Circ Physiol. 2022 07 01; 323(1):H165-H175.
    View in: PubMed
    Score: 0.008
  76. Atrial Fibrillation in Heart?Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2022 05; 10(5):336-346.
    View in: PubMed
    Score: 0.008
  77. Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC Heart Fail. 2022 06; 10(6):415-427.
    View in: PubMed
    Score: 0.008
  78. Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg. 2002 Apr; 123(4):707-14.
    View in: PubMed
    Score: 0.008
  79. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002 Mar 26; 105(12):1503-8.
    View in: PubMed
    Score: 0.008
  80. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002 Mar 19; 105(11):1387-93.
    View in: PubMed
    Score: 0.008
  81. Ensemble machine learning model identifies patients with HFpEF from matrix-related plasma biomarkers. Am J Physiol Heart Circ Physiol. 2022 05 01; 322(5):H798-H805.
    View in: PubMed
    Score: 0.008
  82. Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF. Eur J Heart Fail. 2022 04; 24(4):672-677.
    View in: PubMed
    Score: 0.008
  83. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Eur J Heart Fail. 2022 03; 24(3):551-561.
    View in: PubMed
    Score: 0.008
  84. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 09; 24(9):1591-1598.
    View in: PubMed
    Score: 0.008
  85. Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure. J Am Heart Assoc. 2022 01 18; 11(2):e024095.
    View in: PubMed
    Score: 0.007
  86. Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF. PLoS One. 2022; 17(1):e0262479.
    View in: PubMed
    Score: 0.007
  87. Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes. Nat Commun. 2022 01 11; 13(1):203.
    View in: PubMed
    Score: 0.007
  88. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022 03; 24(3):497-509.
    View in: PubMed
    Score: 0.007
  89. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. J Am Heart Assoc. 2021 12 07; 10(23):e021494.
    View in: PubMed
    Score: 0.007
  90. Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 11 02; 10(21):e022930.
    View in: PubMed
    Score: 0.007
  91. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021 09 21; 42(36):3741-3752.
    View in: PubMed
    Score: 0.007
  92. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021 09 11; 398(10304):991-1001.
    View in: PubMed
    Score: 0.007
  93. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 08 03; 10(15):e019545.
    View in: PubMed
    Score: 0.007
  94. Integrating High-Sensitivity Troponin T and?Sacubitril/Valsartan Treatment in?HFpEF: The PARAGON-HF Trial. JACC Heart Fail. 2021 09; 9(9):627-635.
    View in: PubMed
    Score: 0.007
  95. Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial. Eur J Heart Fail. 2021 12; 23(12):2085-2090.
    View in: PubMed
    Score: 0.007
  96. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.
    View in: PubMed
    Score: 0.007
  97. Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. J Card Fail. 2021 09; 27(9):1027-1030.
    View in: PubMed
    Score: 0.007
  98. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clin Res Cardiol. 2021 Aug; 110(8):1334-1349.
    View in: PubMed
    Score: 0.007
  99. Incidence and Outcomes of Pneumonia in Patients With Heart?Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.
    View in: PubMed
    Score: 0.007
  100. Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Circ Heart Fail. 2021 04; 14(4):e007901.
    View in: PubMed
    Score: 0.007
  101. Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy. J Am Coll Cardiol. 2001 Mar 15; 37(4):1080-4.
    View in: PubMed
    Score: 0.007
  102. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ Heart Fail. 2021 03; 14(3):e008052.
    View in: PubMed
    Score: 0.007
  103. Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. Eur J Heart Fail. 2021 08; 23(8):1346-1356.
    View in: PubMed
    Score: 0.007
  104. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. Eur J Heart Fail. 2021 05; 23(5):776-784.
    View in: PubMed
    Score: 0.007
  105. Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. J Am Heart Assoc. 2021 03 16; 10(6):e018127.
    View in: PubMed
    Score: 0.007
  106. Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. Am Heart J. 2021 07; 237:45-53.
    View in: PubMed
    Score: 0.007
  107. Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail. 2021 04; 8(2):1706-1710.
    View in: PubMed
    Score: 0.007
  108. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
    View in: PubMed
    Score: 0.007
  109. Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. Am J Med. 2021 06; 134(6):797-804.
    View in: PubMed
    Score: 0.007
  110. Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. ESC Heart Fail. 2021 04; 8(2):1130-1138.
    View in: PubMed
    Score: 0.007
  111. The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice. Hum Mol Genet. 2021 01 06; 29(21):3504-3515.
    View in: PubMed
    Score: 0.007
  112. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clin Res Cardiol. 2021 Aug; 110(8):1234-1248.
    View in: PubMed
    Score: 0.007
  113. Reply: Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF. J Am Coll Cardiol. 2020 11 17; 76(20):2417-2418.
    View in: PubMed
    Score: 0.007
  114. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. JAMA. 2020 10 20; 324(15):1522-1531.
    View in: PubMed
    Score: 0.007
  115. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. 2020 11; 22(11):2093-2101.
    View in: PubMed
    Score: 0.007
  116. Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. Am J Med. 2021 04; 134(4):e252-e263.
    View in: PubMed
    Score: 0.007
  117. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020 11; 22(11):2056-2064.
    View in: PubMed
    Score: 0.007
  118. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 12; 22(12):2370-2379.
    View in: PubMed
    Score: 0.007
  119. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart?Failure Cause: A PARADIGM-HF Analysis. JACC Heart Fail. 2020 10; 8(10):844-855.
    View in: PubMed
    Score: 0.007
  120. Loop Diuretic Prescription and 30-Day?Outcomes in Older Patients With?Heart?Failure. J Am Coll Cardiol. 2020 08 11; 76(6):669-679.
    View in: PubMed
    Score: 0.007
  121. Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. J Card Fail. 2020 Oct; 26(10):876-884.
    View in: PubMed
    Score: 0.007
  122. Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020 09; 22(9):1662-1671.
    View in: PubMed
    Score: 0.007
  123. Myocardial Infarction in Heart?Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. JACC Heart Fail. 2020 08; 8(8):618-626.
    View in: PubMed
    Score: 0.007
  124. The prevalence and importance of frailty in heart failure with reduced ejection fraction?-?an analysis of PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 11; 22(11):2123-2133.
    View in: PubMed
    Score: 0.007
  125. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Am J Med. 2020 10; 133(10):1187-1194.
    View in: PubMed
    Score: 0.007
  126. Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiol. 2020 04 01; 5(4):432-441.
    View in: PubMed
    Score: 0.007
  127. Reply: Different Phenotype Characterization in PARAGON-HF: An Unresolved Puzzle in Patients With HFpEF. J Am Coll Cardiol. 2020 03 31; 75(12):1501-1502.
    View in: PubMed
    Score: 0.007
  128. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart?Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020 05; 8(5):372-381.
    View in: PubMed
    Score: 0.007
  129. Covariate adjusted reanalysis of the I-Preserve trial. Clin Res Cardiol. 2020 Nov; 109(11):1358-1365.
    View in: PubMed
    Score: 0.007
  130. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart?Failure Position Paper. JACC Heart Fail. 2020 05; 8(5):347-358.
    View in: PubMed
    Score: 0.007
  131. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 02; 13(2):e006541.
    View in: PubMed
    Score: 0.007
  132. Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation. Circ Heart Fail. 2020 02; 13(2):e006696.
    View in: PubMed
    Score: 0.007
  133. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). Am Heart J. 2020 04; 222:183-190.
    View in: PubMed
    Score: 0.007
  134. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020 03; 22(3):528-538.
    View in: PubMed
    Score: 0.006
  135. Echocardiographic Features of Patients?With Heart?Failure and Preserved?Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 12 10; 74(23):2858-2873.
    View in: PubMed
    Score: 0.006
  136. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 12; 12(12):e006539.
    View in: PubMed
    Score: 0.006
  137. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation. 2020 02 04; 141(5):338-351.
    View in: PubMed
    Score: 0.006
  138. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 02 04; 141(5):352-361.
    View in: PubMed
    Score: 0.006
  139. Randomized trial of partial versus complete chordal preservation methods of mitral valve replacement: A preliminary report. Circulation. 1999 Nov 09; 100(19 Suppl):II90-4.
    View in: PubMed
    Score: 0.006
  140. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 10 22; 140(17):1369-1379.
    View in: PubMed
    Score: 0.006
  141. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 10 24; 381(17):1609-1620.
    View in: PubMed
    Score: 0.006
  142. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. J Am Heart Assoc. 2019 09 03; 8(17):e013114.
    View in: PubMed
    Score: 0.006
  143. Age-Related Characteristics and Outcomes of Patients With Heart?Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 08 06; 74(5):601-612.
    View in: PubMed
    Score: 0.006
  144. Health-Related Quality of Life in Heart?Failure With Preserved Ejection?Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 10; 7(10):862-874.
    View in: PubMed
    Score: 0.006
  145. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail. 2019 08; 21(8):974-984.
    View in: PubMed
    Score: 0.006
  146. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 06; 7(6):457-465.
    View in: PubMed
    Score: 0.006
  147. Mitochondrial biogenesis induced by the ?2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. Kidney Int. 2019 09; 96(3):656-673.
    View in: PubMed
    Score: 0.006
  148. Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). Am Heart J. 2019 08; 214:18-27.
    View in: PubMed
    Score: 0.006
  149. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2019 05; 7(5):418-427.
    View in: PubMed
    Score: 0.006
  150. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The?PARADIGM-HF?Trial. J Am Coll Cardiol. 2019 03 26; 73(11):1264-1272.
    View in: PubMed
    Score: 0.006
  151. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circ Heart Fail. 2019 03; 12(3):e005766.
    View in: PubMed
    Score: 0.006
  152. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019 03; 21(3):337-341.
    View in: PubMed
    Score: 0.006
  153. Income Inequality and Outcomes in Heart?Failure: A Global Between-Country Analysis. JACC Heart Fail. 2019 04; 7(4):336-346.
    View in: PubMed
    Score: 0.006
  154. Elevated Wall Tension Leads to Reduced miR-133a in the Thoracic Aorta by Exosome Release. J Am Heart Assoc. 2019 01 08; 8(1):e010332.
    View in: PubMed
    Score: 0.006
  155. Differential Impact of Heart Failure With?Reduced Ejection Fraction on?Men?and?Women. J Am Coll Cardiol. 2019 01 08; 73(1):29-40.
    View in: PubMed
    Score: 0.006
  156. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018 12 11; 138(24):2763-2773.
    View in: PubMed
    Score: 0.006
  157. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019 May; 21(5):577-587.
    View in: PubMed
    Score: 0.006
  158. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019 01; 21(1):40-49.
    View in: PubMed
    Score: 0.006
  159. Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review. JAMA Cardiol. 2018 12 01; 3(12):1232-1243.
    View in: PubMed
    Score: 0.006
  160. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiol. 2018 12 01; 3(12):1226-1231.
    View in: PubMed
    Score: 0.006
  161. Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al. ESC Heart Fail. 2018 12; 5(6):1069-1071.
    View in: PubMed
    Score: 0.006
  162. Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 2018 Oct; 24(10):682-694.
    View in: PubMed
    Score: 0.006
  163. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circ Heart Fail. 2018 10; 11(10):e005133.
    View in: PubMed
    Score: 0.006
  164. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018 12; 20(12):1701-1709.
    View in: PubMed
    Score: 0.006
  165. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019 01; 21(1):23-36.
    View in: PubMed
    Score: 0.006
  166. Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. Am J Med. 2018 12; 131(12):1473-1481.
    View in: PubMed
    Score: 0.006
  167. Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. Am Heart J. 2018 11; 205:1-11.
    View in: PubMed
    Score: 0.006
  168. Safety and Feasibility of a Nocturnal Heart Rate Elevation-Exploration of a Novel Treatment Concept. J Card Fail. 2019 01; 25(1):67-71.
    View in: PubMed
    Score: 0.006
  169. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018 07; 11(7):e004962.
    View in: PubMed
    Score: 0.006
  170. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018 06 01; 3(6):498-505.
    View in: PubMed
    Score: 0.006
  171. Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. Int J Cardiol. 2018 Sep 01; 266:187-192.
    View in: PubMed
    Score: 0.006
  172. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018 06; 6(6):489-498.
    View in: PubMed
    Score: 0.006
  173. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 04; 11(4):e004745.
    View in: PubMed
    Score: 0.006
  174. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018 03; 15(3):e1002541.
    View in: PubMed
    Score: 0.006
  175. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of?Heart Failure. JACC Heart Fail. 2018 07; 6(7):564-569.
    View in: PubMed
    Score: 0.006
  176. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2018 04; 20(4):760-768.
    View in: PubMed
    Score: 0.006
  177. Cardiac macrophages promote diastolic dysfunction. J Exp Med. 2018 02 05; 215(2):423-440.
    View in: PubMed
    Score: 0.006
  178. Type of Atrial Fibrillation and Outcomes in?Patients With Heart Failure and Reduced?Ejection?Fraction. J Am Coll Cardiol. 2017 Nov 14; 70(20):2490-2500.
    View in: PubMed
    Score: 0.006
  179. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov; 10(11).
    View in: PubMed
    Score: 0.006
  180. Heart Rate and Outcomes in Hospitalized?Patients With Heart Failure With Preserved Ejection?Fraction. J Am Coll Cardiol. 2017 Oct 10; 70(15):1861-1871.
    View in: PubMed
    Score: 0.006
  181. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.006
  182. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017 Aug; 10(8).
    View in: PubMed
    Score: 0.006
  183. Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017 07 06; 377(1):41-51.
    View in: PubMed
    Score: 0.005
  184. Angiotensin Receptor Neprilysin Inhibition?in Heart Failure With Preserved?Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. JACC Heart Fail. 2017 07; 5(7):471-482.
    View in: PubMed
    Score: 0.005
  185. Evaluation of systolic and diastolic properties of hypertensive heart failure using speckle-tracking echocardiography with high volume rates. Heart Vessels. 2017 Oct; 32(10):1202-1213.
    View in: PubMed
    Score: 0.005
  186. Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience. Am Heart J. 1997 Jun; 133(6):648-55.
    View in: PubMed
    Score: 0.005
  187. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017 May 30; 135(22):e1054-e1091.
    View in: PubMed
    Score: 0.005
  188. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017 04 14; 38(15):1132-1143.
    View in: PubMed
    Score: 0.005
  189. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 05; 5(5):333-340.
    View in: PubMed
    Score: 0.005
  190. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. Am Heart J. 2017 Jun; 188:35-41.
    View in: PubMed
    Score: 0.005
  191. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J. 2017 Mar 07; 38(10):742-750.
    View in: PubMed
    Score: 0.005
  192. Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? JACC Clin Electrophysiol. 2017 03; 3(3):291-298.
    View in: PubMed
    Score: 0.005
  193. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017 Feb 21; 135(8):724-735.
    View in: PubMed
    Score: 0.005
  194. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 01 01; 2(1):79-85.
    View in: PubMed
    Score: 0.005
  195. Natriuretic Peptides, 6-Min Walk Test, and?Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. J Am Coll Cardiol. 2016 Dec 20; 68(24):2690-2707.
    View in: PubMed
    Score: 0.005
  196. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 11 29; 134(22):1785-1787.
    View in: PubMed
    Score: 0.005
  197. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017 01; 19(1):129-137.
    View in: PubMed
    Score: 0.005
  198. Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Nov; 9(11).
    View in: PubMed
    Score: 0.005
  199. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiol. 2016 09 01; 1(6):666-72.
    View in: PubMed
    Score: 0.005
  200. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. Circ Heart Fail. 2016 09; 9(9).
    View in: PubMed
    Score: 0.005
  201. Influence of Sacubitril/Valsartan (LCZ696)?on?30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol. 2016 07 19; 68(3):241-248.
    View in: PubMed
    Score: 0.005
  202. Efficacy of Sacubitril/Valsartan Relative to?a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016 10; 4(10):816-822.
    View in: PubMed
    Score: 0.005
  203. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016 Jul 05; 134(1):73-90.
    View in: PubMed
    Score: 0.005
  204. Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. J Card Fail. 2016 Oct; 22(10):753-60.
    View in: PubMed
    Score: 0.005
  205. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. 2016 Nov 01; 37(41):3167-3174.
    View in: PubMed
    Score: 0.005
  206. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. J Card Fail. 2017 Jan; 23(1):20-28.
    View in: PubMed
    Score: 0.005
  207. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016 Oct; 18(10):1228-1234.
    View in: PubMed
    Score: 0.005
  208. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 06; 9(6).
    View in: PubMed
    Score: 0.005
  209. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. Eur J Heart Fail. 2016 08; 18(8):1021-31.
    View in: PubMed
    Score: 0.005
  210. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016 Jun 07; 133(23):2254-62.
    View in: PubMed
    Score: 0.005
  211. The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio. Int J Cardiol. 2016 Jul 15; 215:521-6.
    View in: PubMed
    Score: 0.005
  212. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Apr; 9(4):e002763.
    View in: PubMed
    Score: 0.005
  213. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar; 9(3):e002744.
    View in: PubMed
    Score: 0.005
  214. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.005
  215. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail. 2016 Feb; 4(2):152-158.
    View in: PubMed
    Score: 0.005
  216. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. N Engl J Med. 2015 Dec 03; 373(23):2289-90.
    View in: PubMed
    Score: 0.005
  217. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015 Nov 10; 66(19):2059-2071.
    View in: PubMed
    Score: 0.005
  218. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial. J Card Fail. 2016 Apr; 22(4):283-93.
    View in: PubMed
    Score: 0.005
  219. HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis. Circ Heart Fail. 2015 Nov; 8(6):1094-104.
    View in: PubMed
    Score: 0.005
  220. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep; 17(9):925-35.
    View in: PubMed
    Score: 0.005
  221. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015 Oct 07; 36(38):2576-84.
    View in: PubMed
    Score: 0.005
  222. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circ Heart Fail. 2015 Jul; 8(4):717-24.
    View in: PubMed
    Score: 0.005
  223. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2015 Jun; 3(6):478-486.
    View in: PubMed
    Score: 0.005
  224. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015 Aug 07; 36(30):1990-7.
    View in: PubMed
    Score: 0.005
  225. Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. Circ Heart Fail. 2015 Jul; 8(4):733-40.
    View in: PubMed
    Score: 0.005
  226. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015 Jun; 3(6):487-496.
    View in: PubMed
    Score: 0.005
  227. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC Heart Fail. 2015 Jun; 3(6):429-441.
    View in: PubMed
    Score: 0.005
  228. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail. 2015 Aug; 17(8):809-17.
    View in: PubMed
    Score: 0.005
  229. Left ventricular layer function in hypertension assessed by myocardial strain rate using novel one-beat real-time three-dimensional speckle tracking echocardiography with high volume rates. Hypertens Res. 2015 Aug; 38(8):551-9.
    View in: PubMed
    Score: 0.005
  230. Response to letters regarding article, "systolic and diastolic mechanics in stress cardiomyopathy". Circulation. 2015 Mar 10; 131(10):e372.
    View in: PubMed
    Score: 0.005
  231. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015 Feb 14; 36(7):434-9.
    View in: PubMed
    Score: 0.005
  232. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015 May; 17(5):510-7.
    View in: PubMed
    Score: 0.005
  233. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail. 2015 Feb; 17(2):169-76.
    View in: PubMed
    Score: 0.005
  234. A novel ultrasound predictor of pulmonary capillary wedge pressure assessed by the combination of left atrial volume and function: A speckle tracking echocardiography study. J Cardiol. 2015 Sep; 66(3):253-62.
    View in: PubMed
    Score: 0.005
  235. Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST). Circ Heart Fail. 2015 Jan; 8(1):17-24.
    View in: PubMed
    Score: 0.005
  236. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation. 2015 Jan 06; 131(1):43-53.
    View in: PubMed
    Score: 0.005
  237. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 Jan 06; 131(1):54-61.
    View in: PubMed
    Score: 0.005
  238. Dual-source CT imaging to plan transcatheter aortic valve replacement: accuracy for diagnosis of obstructive coronary artery disease. Radiology. 2015 Apr; 275(1):80-8.
    View in: PubMed
    Score: 0.005
  239. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2014 Nov; 16(11):1175-82.
    View in: PubMed
    Score: 0.005
  240. Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? J Am Coll Cardiol. 2014 Oct 07; 64(14):1535-6.
    View in: PubMed
    Score: 0.005
  241. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail. 2014 Nov; 7(6):953-9.
    View in: PubMed
    Score: 0.005
  242. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol. 2014 Sep 16; 64(11):1106-13.
    View in: PubMed
    Score: 0.005
  243. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014 Nov; 7(6):960-6.
    View in: PubMed
    Score: 0.005
  244. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11; 371(11):993-1004.
    View in: PubMed
    Score: 0.004
  245. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 Oct; 16(10):1096-103.
    View in: PubMed
    Score: 0.004
  246. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014 Sep; 7(5):740-51.
    View in: PubMed
    Score: 0.004
  247. The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. JACC Cardiovasc Imaging. 2014 Sep; 7(9):870-8.
    View in: PubMed
    Score: 0.004
  248. Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol. 2014 Sep 01; 307(5):H752-61.
    View in: PubMed
    Score: 0.004
  249. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014 Dec 21; 35(48):3442-51.
    View in: PubMed
    Score: 0.004
  250. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014 Jul; 16(7):817-25.
    View in: PubMed
    Score: 0.004
  251. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail. 2014 Jul; 16(7):778-87.
    View in: PubMed
    Score: 0.004
  252. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail. 2014 Jun; 16(6):671-7.
    View in: PubMed
    Score: 0.004
  253. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014 Apr; 2(2):97-112.
    View in: PubMed
    Score: 0.004
  254. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 May; 16(5):535-42.
    View in: PubMed
    Score: 0.004
  255. Systolic and diastolic mechanics in stress cardiomyopathy. Circulation. 2014 Apr 22; 129(16):1659-67.
    View in: PubMed
    Score: 0.004
  256. Myocardial fibroblast-matrix interactions and potential therapeutic targets. J Mol Cell Cardiol. 2014 May; 70:92-9.
    View in: PubMed
    Score: 0.004
  257. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014 Feb 11; 63(5):447-56.
    View in: PubMed
    Score: 0.004
  258. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J. 2014 Jan; 35(1):42-7.
    View in: PubMed
    Score: 0.004
  259. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014 Feb; 127(2):132-9.
    View in: PubMed
    Score: 0.004
  260. Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. Am J Hypertens. 2013 Oct; 26(10):1234-41.
    View in: PubMed
    Score: 0.004
  261. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013 Sep; 15(9):1062-73.
    View in: PubMed
    Score: 0.004
  262. Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med. 2013 Feb; 126(2):150-61.
    View in: PubMed
    Score: 0.004
  263. Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance. Circulation. 1992 Dec; 86(6):1718-26.
    View in: PubMed
    Score: 0.004
  264. Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling. Circ Heart Fail. 2012 Nov; 5(6):803-11.
    View in: PubMed
    Score: 0.004
  265. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J. 2013 Mar; 34(9):676-83.
    View in: PubMed
    Score: 0.004
  266. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 Oct 20; 380(9851):1387-95.
    View in: PubMed
    Score: 0.004
  267. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012 Sep 01; 5(5):571-8.
    View in: PubMed
    Score: 0.004
  268. In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol. 2012 Oct 15; 110(8):1150-5.
    View in: PubMed
    Score: 0.004
  269. Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail. 2012 Jun; 18(6):487-92.
    View in: PubMed
    Score: 0.004
  270. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf. 2012 Mar 01; 35(3):233-44.
    View in: PubMed
    Score: 0.004
  271. The Heart Failure Society of America in 2020: a vision for the future. J Card Fail. 2012 Feb; 18(2):90-3.
    View in: PubMed
    Score: 0.004
  272. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 2012 Mar 01; 5(2):217-25.
    View in: PubMed
    Score: 0.004
  273. The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens. 2011 Sep; 29(9):1829-36.
    View in: PubMed
    Score: 0.004
  274. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):656-64.
    View in: PubMed
    Score: 0.004
  275. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail. 2011 Sep; 4(5):561-8.
    View in: PubMed
    Score: 0.004
  276. Left ventricular function after surgical correction of chronic mitral regurgitation. Eur Heart J. 1991 Jul; 12 Suppl B:48-51.
    View in: PubMed
    Score: 0.004
  277. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011 Sep; 4(5):569-77.
    View in: PubMed
    Score: 0.004
  278. Left ventricular diastolic function and exercise capacity in community-dwelling adults =65 years of age without heart failure. Am J Cardiol. 2011 Sep 01; 108(5):735-40.
    View in: PubMed
    Score: 0.004
  279. Chronic aortic and mitral regurgitation. Choosing the optimal time for surgical correction. Cardiol Clin. 1991 May; 9(2):239-53.
    View in: PubMed
    Score: 0.004
  280. Hemodynamic factors associated with acute decompensated heart failure: part 2--use in automated detection. J Card Fail. 2011 May; 17(5):366-73.
    View in: PubMed
    Score: 0.004
  281. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011 May; 4(3):324-31.
    View in: PubMed
    Score: 0.004
  282. Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. Am J Cardiol. 2011 Jan 15; 107(2):321-4.
    View in: PubMed
    Score: 0.003
  283. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011 Jan; 4(1):27-35.
    View in: PubMed
    Score: 0.003
  284. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail. 2010 Sep; 3(5):580-7.
    View in: PubMed
    Score: 0.003
  285. Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem Cell Biol. 2010 Jul; 134(1):23-30.
    View in: PubMed
    Score: 0.003
  286. Mechanical loads and the isovolumic and filling indices of left ventricular relaxation. Prog Cardiovasc Dis. 1990 Mar-Apr; 32(5):333-46.
    View in: PubMed
    Score: 0.003
  287. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail. 2010 Feb; 16(2):128-34.
    View in: PubMed
    Score: 0.003
  288. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 04; 359(23):2456-67.
    View in: PubMed
    Score: 0.003
  289. Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). Circulation. 2008 Sep 16; 118(12):1241-9.
    View in: PubMed
    Score: 0.003
  290. Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol. 2008 Jul 15; 102(2):203-6.
    View in: PubMed
    Score: 0.003
  291. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008 Mar 18; 51(11):1073-9.
    View in: PubMed
    Score: 0.003
  292. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008 Feb; 10(2):149-56.
    View in: PubMed
    Score: 0.003
  293. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). Am Heart J. 2008 Jan; 155(1):113.e1-8.
    View in: PubMed
    Score: 0.003
  294. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007 Jun 23; 369(9579):2079-87.
    View in: PubMed
    Score: 0.003
  295. Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant. 2007 Feb; 26(2):145-51.
    View in: PubMed
    Score: 0.003
  296. Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol. 2007 Feb 15; 99(4):460-4.
    View in: PubMed
    Score: 0.003
  297. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007 Feb 01; 99(3):393-8.
    View in: PubMed
    Score: 0.003
  298. Myocardial mechanisms causing heart failure early after cardiac transplantation. Transplant Proc. 2006 Nov; 38(9):2999-3003.
    View in: PubMed
    Score: 0.003
  299. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation. 2006 Sep 05; 114(10):1020-7.
    View in: PubMed
    Score: 0.003
  300. Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. Am Heart J. 2006 Aug; 152(2):246-52.
    View in: PubMed
    Score: 0.003
  301. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006 Aug 01; 114(5):397-403.
    View in: PubMed
    Score: 0.003
  302. Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction. Am J Cardiol. 2006 Aug 01; 98(3):383-5.
    View in: PubMed
    Score: 0.003
  303. Chronic heart failure: a report from the Dartmouth Diastole Discourses. Congest Heart Fail. 2006 May-Jun; 12(3):162-5.
    View in: PubMed
    Score: 0.003
  304. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg. 2006 Mar; 131(3):679-85.
    View in: PubMed
    Score: 0.002
  305. Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation. 2006 Jan 17; 113(2):296-304.
    View in: PubMed
    Score: 0.002
  306. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J Thromb Thrombolysis. 2005 Dec; 20(3):147-53.
    View in: PubMed
    Score: 0.002
  307. Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. Circulation. 2005 Nov 15; 112(20):3107-14.
    View in: PubMed
    Score: 0.002
  308. Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients. J Heart Lung Transplant. 2005 Nov; 24(11):1969-72.
    View in: PubMed
    Score: 0.002
  309. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005 Oct; 11(8):576-85.
    View in: PubMed
    Score: 0.002
  310. Left ventricular stress-dimension-shortening relations before and after correction of chronic aortic and mitral regurgitation. Am J Cardiol. 1985 Jul 01; 56(1):99-105.
    View in: PubMed
    Score: 0.002
  311. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation. 2005 May 10; 111(18):2306-12.
    View in: PubMed
    Score: 0.002
  312. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005 Apr; 11(3):191-5.
    View in: PubMed
    Score: 0.002
  313. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail. 2005 Mar; 11(2):124-30.
    View in: PubMed
    Score: 0.002
  314. Evaluation of myocardial function in cardiomyopathic states. Prog Cardiovasc Dis. 1984 Sep-Oct; 27(2):115-32.
    View in: PubMed
    Score: 0.002
  315. Lack of relationship between Doppler indices of diastolic function and left ventricular pressure transients in patients with definite diastolic heart failure. Am Heart J. 2004 Sep; 148(3):E12.
    View in: PubMed
    Score: 0.002
  316. Chronic mitral regurgitation: predictive value of preoperative echocardiographic indexes of left ventricular function and wall stress. J Am Coll Cardiol. 1984 Feb; 3(2 Pt 1):235-42.
    View in: PubMed
    Score: 0.002
  317. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003 Oct; 9(5):354-63.
    View in: PubMed
    Score: 0.002
  318. beta-Adrenergic and endothelin receptor interaction in dilated human cardiomyopathic myocardium. J Card Fail. 2001 Jun; 7(2):129-37.
    View in: PubMed
    Score: 0.002
  319. Preliminary report on high thoracic epidural analgesia: relationship between its therapeutic effects and myocardial blood flow as assessed by stress thallium distribution. J Cardiothorac Vasc Anesth. 2000 Dec; 14(6):657-61.
    View in: PubMed
    Score: 0.002
  320. Left ventricular length-force-shortening relations before and after surgical correction of chronic mitral regurgitation. J Am Coll Cardiol. 1998 Jan; 31(1):180-5.
    View in: PubMed
    Score: 0.001
  321. Effect of catheter positioning on the variability of measured gradient in aortic stenosis. Cathet Cardiovasc Diagn. 1993 Dec; 30(4):287-92.
    View in: PubMed
    Score: 0.001
  322. Aortic valve resistance as an adjunct to the Gorlin formula in assessing the severity of aortic stenosis in symptomatic patients. J Am Coll Cardiol. 1992 Dec; 20(7):1517-23.
    View in: PubMed
    Score: 0.001
  323. Chronotropic incompetence: a common and progressive finding in pacemaker patients. Am Heart J. 1992 May; 123(5):1216-9.
    View in: PubMed
    Score: 0.001
  324. Dialysis-induced alterations in left ventricular filling: mechanisms and clinical significance. Am J Kidney Dis. 1991 Mar; 17(3):277-85.
    View in: PubMed
    Score: 0.001
  325. Hemodynamic correlates of left ventricular versus right ventricular radionuclide volumetric responses to vasodilator therapy in congestive heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol. 1987 May 01; 59(12):1131-7.
    View in: PubMed
    Score: 0.001
  326. Contribution of reduced mitral regurgitant volume to vasodilator effect in severe left ventricular failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1986 Nov 01; 58(10):1046-50.
    View in: PubMed
    Score: 0.001
  327. Comparison of left and right ventricular end-systolic pressure-volume relations in congestive heart failure. J Am Coll Cardiol. 1985 Jun; 5(6):1326-34.
    View in: PubMed
    Score: 0.001
  328. Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements. Circulation. 1985 Feb; 71(2):266-72.
    View in: PubMed
    Score: 0.001
  329. Vasodilator effect on right ventricular function in congestive heart failure and pulmonary hypertension: end-systolic pressure--volume relation. Am J Cardiol. 1984 Jul 01; 54(1):132-6.
    View in: PubMed
    Score: 0.001
  330. Serial changes in left ventricular function after correction of chronic aortic regurgitation. Dependence on early changes in preload and subsequent regression of hypertrophy. Am J Cardiol. 1983 Feb; 51(3):476-82.
    View in: PubMed
    Score: 0.001
  331. Immunologic tests of value in diagnosis. 1. Acute phase reactants and autoantibodies. Postgrad Med. 1981 Aug; 70(2):163-78.
    View in: PubMed
    Score: 0.000
  332. Immunologic tests of value in diagnosis. 2. Complement. Postgrad Med. 1981 Aug; 70(2):183-8.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.